Press release
Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon
DelveInsight's "Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Progressive Supranuclear Palsy, offering comprehensive insights into the Progressive Supranuclear Palsy revenue trends, prevalence, and treatment landscape. The report delves into key Progressive Supranuclear Palsy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Progressive Supranuclear Palsy therapies. Additionally, we cover the landscape of Progressive Supranuclear Palsy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Progressive Supranuclear Palsy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Progressive Supranuclear Palsy space.
To Know in detail about the Progressive Supranuclear Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive Supranuclear Palsy Market Forecast [https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Progressive Supranuclear Palsy Market Report:
*
The Progressive Supranuclear Palsy market size was valued ~USD 8.3 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In October 2024, GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that the topline results from the Phase 2a clinical trial (the "Phase 2a PSP Clinical Trial") of GV1001, an experimental peptide drug for treating progressive supranuclear palsy ("PSP"), were presented at "Neuro2024."
*
In September 2024, Ferrer, a B Corp-certified global pharmaceutical company, announced the administration of the first dose in the Phase II clinical trial, PROSPER. The trial aims to assess the safety and efficacy of FNP-223,1, a new therapy designed to slow the progression of Progressive Supranuclear Palsy (PSP).
*
In 2022, the US held the largest market share for PSP, accounting for around 44% of the total PSP market. This is expected to grow significantly during the study period with the introduction of new market players.
*
In 2022, the PSP market size in EU4 and the UK was approximately USD 2.4 million. DelveInsight's analysis indicates that the market is expected to grow during the study period.
*
In 2022, Germany had the largest market size in EU4 and the UK, with approximately USD 0.6 million, while Spain had the smallest. The market is projected to grow, with Germany expected to maintain the largest share, followed by Italy in 2032.
*
Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma's, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others
*
Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others
*
The Progressive Supranuclear Palsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Supranuclear Palsy pipeline products will significantly revolutionize the Progressive Supranuclear Palsy market dynamics.
*
In 2022, the total number of prevalent Progressive Supranuclear Palsy (PSP) cases was estimated to be around 80,706 across the 7MM.
*
In 2022, Japan had the highest prevalence of Progressive Supranuclear Palsy (PSP), contributing almost 29%, while Spain had the lowest, accounting for about 7% of the total prevalent cases.
*
According to DelveInsight analysis, in 2022, the United States had the highest number of diagnosed prevalent cases, representing approximately 33% of the total cases across the 7MM countries.
*
Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of PSP, with approximately 1,646 cases, while Spain had the lowest, with around 941 cases in 2022.
*
In 2022, approximately 3,077 males and 2,674 females in the US were diagnosed with PSP.
Progressive Supranuclear Palsy Overview
Progressive supranuclear palsy (PSP) is a rare, degenerative neurological disorder that affects movement, balance, vision, speech, and swallowing. It is caused by the deterioration of cells in the brain, particularly in areas that control these functions, such as the brainstem and basal ganglia. Symptoms of PSP typically include difficulty with balance and walking, eye movement problems (especially looking up or down), stiffness, and slurred speech. PSP progresses over time, and there is currently no cure, though treatment can help manage symptoms. It is often misdiagnosed as Parkinson's disease due to overlapping symptoms.
Get a Free sample for the Progressive Supranuclear Palsy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market [https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Progressive Supranuclear Palsy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Progressive Supranuclear Palsy Epidemiology Segmentation:
The Progressive Supranuclear Palsy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalent Cases of PSP in the 7MM
*
Total Diagnosed Prevalent Cases of PSP in the 7MM
*
Gender-specific Diagnosed Prevalent Cases of PSP in the 7MM
*
Phenotype-specific Diagnosed Prevalent Cases of PSP in the 7MM
*
Comorbidity Associated Cases with PSP in the 7MM
Download the report to understand which factors are driving Progressive Supranuclear Palsy epidemiology trends @ Progressive Supranuclear Palsy Epidemiology Forecast [https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Progressive Supranuclear Palsy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Progressive Supranuclear Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Progressive Supranuclear Palsy Therapies and Key Companies
*
BRAVYL (fasudil): Woolsey Pharmaceutical/Asahi Kasei Pharma
*
AZP2006 (ezeprogind): AlzProtect
*
AMX0035: Amylyx Pharmaceuticals
*
TPN-101/OBP-601 (censavudine): Transposon Therapeutics/Oncolys Biopharma's
*
ASN90: Ferrer/Asceneuron
*
GV1001: GemVax & Kael
*
FNP-223: Ferrer Internacional S.A.
*
Davunetide: Allon Therapeutics
*
AMX0035: Amylyx Pharmaceuticals
*
NBMI: EmeraMed
Discover more about therapies set to grab major Progressive Supranuclear Palsy market share @ Progressive Supranuclear Palsy Treatment Landscape [https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Progressive Supranuclear Palsy Market Strengths
*
The new MDS diagnostic criteria for PSP expands the clinical spectrum of the disease by incorporating conditions suggestive of PSP and a variety of symptomatic PSP phenotypes.
*
Advocacy and support organizations are dedicated to raising awareness, providing resources, and supporting PSP-affected individuals and families.
*
Improvement in understanding PSP pathogenesis has led to the discovery of potential therapies that target tau protein through various modes of actions
Progressive Supranuclear Palsy Market Opportunities
*
The lack of approved therapies provides lucrative opportunities for pharma players to develop disease-modifying therapies and capitalize on the untapped market
*
Increasing research can lead to a deeper understanding of PSP, including its underlying mechanisms, risk factors, and potential therapeutic targets
*
Research focusing on the identification of better imaging and biofluid biomarkers will promote early and accurate diagnosis enrollment of appropriate patients who are likely to show more clear beneficial effects in clinical trials
Scope of the Progressive Supranuclear Palsy Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma's, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others
*
Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others
*
Progressive Supranuclear Palsy Therapeutic Assessment: Progressive Supranuclear Palsy current marketed and Progressive Supranuclear Palsy emerging therapies
*
Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy market drivers and Progressive Supranuclear Palsy market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Progressive Supranuclear Palsy Unmet Needs, KOL's views, Analyst's views, Progressive Supranuclear Palsy Market Access and Reimbursement
To know more about Progressive Supranuclear Palsy companies working in the treatment market, visit @ Progressive Supranuclear Palsy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Progressive Supranuclear Palsy Market Report Introduction
2. Executive Summary for Progressive Supranuclear Palsy
3. SWOT analysis of Progressive Supranuclear Palsy
4. Progressive Supranuclear Palsy Patient Share (%) Overview at a Glance
5. Progressive Supranuclear Palsy Market Overview at a Glance
6. Progressive Supranuclear Palsy Disease Background and Overview
7. Progressive Supranuclear Palsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Progressive Supranuclear Palsy
9. Progressive Supranuclear Palsy Current Treatment and Medical Practices
10. Progressive Supranuclear Palsy Unmet Needs
11. Progressive Supranuclear Palsy Emerging Therapies
12. Progressive Supranuclear Palsy Market Outlook
13. Country-Wise Progressive Supranuclear Palsy Market Analysis (2019-2032)
14. Progressive Supranuclear Palsy Market Access and Reimbursement of Therapies
15. Progressive Supranuclear Palsy Market Drivers
16. Progressive Supranuclear Palsy Market Barriers
17. Progressive Supranuclear Palsy Appendix
18. Progressive Supranuclear Palsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=progressive-supranuclear-palsy-market-statistics-expected-to-experience-major-growth-by-2032-according-to-delveinsight-woolsey-pharma-asahi-kasei-pharma-alzprotect-amylyx-pharma-transposon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon here
News-ID: 3785431 • Views: …
More Releases from ABNewswire
Empowering Authors Worldwide with Comprehensive Support for Every Stage of the P …
Stories have the power to connect, inspire, and transcend boundaries. At the heart of this universal truth lies InkArray, a dedicated partner for authors seeking to transform their ideas into timeless books. InkArray isn't just a publishing service; it's a platform that empowers storytellers to share their voices with the world.
With a deep understanding of the challenges authors face, InkArray offers a supportive and professional environment to bring stories to…
Introducing Bookemo - Revolutionizing Book Publishing for Authors Worldwide
In a world where storytelling knows no boundaries, Bookemo emerges as a beacon of hope for authors across the globe. From budding writers with a story to tell to seasoned authors seeking professional polish, Bookemo is revolutionizing the book publishing industry. The company's mission is simple yet profound: to empower authors by providing a comprehensive suite of services that transforms their ideas into beautifully crafted books.
Bookemo's vision goes beyond publishing-it's…
Integral Theory: Body, Mind, Heart, & Soul By Douglas Mercer
Have you ever wondered if there is an interweaving design to all the parts of life and if they all fit together in some kind of wonderful multi-dimensional tapestry?
Image: https://www.abnewswire.com/upload/2025/01/3616af230f1312a1191a59ffddb5bbd7.PNG
Douglas Mercer breaks down the main aspects of life and gives you a history and evolution of our understanding of what they mean for us individually.
Learn how Integral Theory (developed by Ken Wilber) pools knowledge from many religions, philosophies, and sciences…
Self Publishing Guides Launches Comprehensive Resource Platform for Aspiring Aut …
In response to the rapidly expanding self-publishing industry, Self Publishing Guides announces the launch of its comprehensive educational platform designed specifically for aspiring authors. This innovative resource hub addresses the critical need for reliable, accessible guidance in the complex world of self-publishing.
With the self-publishing market experiencing unprecedented growth, new authors often find themselves overwhelmed by the multifaceted publishing process. Self Publishing Guides fills this gap by providing clear, actionable guidance…
More Releases for Progressive
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Primary Progressive MS – Strong pipeline in progressive MS indicates a paradig …
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.
Primary progressive multiple sclerosis is primarily characterized by progression of disease activity and the disability amongst the patients. As per the latest report by Pharmascroll, PPMS-…
Catalyst Market Anticipated for Progressive Growth
The global Catalyst market was worth USD 29.28 billion in the year 2016 and is anticipated to reach roughly USD 40.92 billion by 2025, while registering itself at a compound annual growth rate (CAGR) of 3.79% during the forecast period. Catalyst is known to be an element that increases the rate of chemical reaction without undertaking any kind of chemical change itself. Generally, reactions take place rapidly by utilizing catalysts…
Neurorehabilitation Devices Market Anticipated for Progressive Growth
Neurorehabilitation helps improve the patient’s ability to function independently after he is diagnosed with conditions such as stroke, multiple sclerosis, brain tumor, Parkinson’s disease, epilepsy and traumatic brain injury among other neurological disorders. Neurorehabilitation is a multi-modal, multi-disciplinary approach to help such patients to improve their physiological functioning. Neurorehabilitation can be broadly classified into three coordinated phases, viz. intermediate care, acute rehabilitation and occupational rehabilitation. Patients undergoing neurorehabilitation usually go…
Progressive Supranuclear Palsy-Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2017, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
